BeiGene

About BeiGene

BeiGene is a global biotechnology company focused on discovering, developing, and commercialising innovative medicines to improve treatment outcomes for patients with cancer. Founded in 2010, the company has rapidly grown to become a leader in the field of oncology, with a commitment to advancing the science of cancer treatment.

At the core of BeiGene’s mission is the belief that every patient deserves access to effective therapies. The company is dedicated to developing targeted therapies that address the underlying genetic drivers of cancer, thereby providing personalised treatment options for patients.

BeiGene’s research and development efforts are supported by a robust pipeline of drug candidates, including both small molecules and biologics. The company has made significant strides in the development of novel therapies for various types of cancer, including hematological malignancies and solid tumours.

In addition to its strong focus on R&D, BeiGene is committed to building a sustainable business model that prioritises patient access and affordability. The company collaborates with healthcare providers, payers, and patient advocacy groups to ensure that its therapies reach those who need them most.

With a global presence, BeiGene operates in multiple countries, including the United States, China, and Europe. The company’s headquarters are located in Beijing, China, but it has established a significant footprint in the UK as part of its international expansion strategy.

As BeiGene continues to grow, it remains steadfast in its vision to transform the treatment landscape for cancer patients worldwide. By leveraging cutting-edge technology and innovative research, BeiGene aims to make a lasting impact on the lives of patients and their families.

• Founded: 2010
• Focus: Oncology
• Headquarters: Beijing, China
• Global Presence: USA, China, Europe, UK